Condition (MeSH)
Catalepsy
ClinicalTrials.gov lists 2 trials for Catalepsy or a narrower condition beneath it. Investigación en Hemofilia y Fisioterapia has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
4 sections measured, none recorded · 1 not measured yet · 1 not computed
2 of the 2 trials are tagged with Catalepsy itself; the rest are tagged with a narrower condition beneath it.
When did Catalepsy trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2019 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Catalepsy trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Not applicable | 2 |
How many Catalepsy trials are recruiting? (1)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Catalepsy trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Investigación en Hemofilia y Fisioterapia | 1 |
Which publications cover Catalepsy? (13)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Pharmacological interaction of Galphimia glauca extract and natural galphimines with Ketamine and Haloperidol on different behavioral tests. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2018 | Yes |
| Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. | Neuropharmacology | 2005 | Yes |
| Narcolepsy-cataplexy. I. Clinical and electrophysiologic characteristics. | Archives of neurology | 1982 | Yes |
| Bee Venom Alleviates Motor Deficits and Modulates the Transfer of Cortical Information through the Basal Ganglia in Rat Models of Parkinson's Disease. | PloS one | 2015 | No |
| Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats. | Synapse (New York, N.Y.) | 2010 | No |
Showing 5 of 13 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.